Vinorelbine Ditartrate Solid Oral Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Vinorelbine ditartrate, a key anticancer agent, is unstable in the solid state, making it challenging to develop stable solid oral forms that maintain bioavailability and safety, particularly due to its sensitivity to temperature and handling as a powder.
Innovation Solution
Development of solid oral forms using conventional excipients such as diluents, binders, disintegrating agents, and lubricants, which are manufactured through standard methods like dry or wet granulation, allowing for stable storage at 5°C for at least 24 months without freezing, and ensuring bioavailability comparable to existing liquid forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If vinorelbine ditartrate is formulated as a solid oral form using conventional excipients, then patient comfort and treatment adherence are improved, but the stability of the active ingredient deteriorates due to its sensitivity to temperature and handling as a powder
Solution Approach 1:
The patent uses specific excipients as intermediaries to protect vinorelbine ditartrate from environmental factors. Magnesium stearate and stearic acid form protective layers around the active ingredient particles, reducing direct exposure to moisture and oxygen. The disintegrating agents and binders create a matrix that stabilizes the salt during storage while enabling controlled release during dissolution.
Solution Approach 2:
The patent modifies physical parameters of the formulation by controlling particle size distribution, moisture content, and density of the solid oral form. By optimizing these parameters within specific ranges, the formulation achieves adequate stability at higher temperatures and humidities while maintaining bioavailability. The granulation process transforms the powder into granules with improved flow and stability characteristics.
2Ease of manufacture
If vinorelbine ditartrate is stored as a powder, then handling and manufacturing are simplified, but health and environment risks increase due to cytotoxic compound exposure
Solution Approach 1:
The patent employs coating techniques to create thin film layers around vinorelbine ditartrate particles or within the tablet matrix. These film barriers prevent direct contact between the cytotoxic powder and handlers during manufacturing and storage, reducing exposure risks while maintaining ease of handling. The coating also prevents dust formation and facilitates safer disposal.
3Reliability
If vinorelbine ditartrate is formulated in liquid solution form, then bioavailability is improved, but manufacturing complexity and storage requirements increase due to need for freezing conditions
Solution Approach 1:
The patent utilizes phase transition principles by formulating the drug as a solid oral form that transitions to dissolved state in the gastrointestinal fluid. This solid-to-dissolved transition occurs in vivo, providing the bioavailability benefits of liquid formulations without the storage complexities. The excipients are selected to facilitate rapid dissolution after oral administration, achieving over 80% release within 30 minutes.
Data Source
AI summary
A stable pharmaceutical composition comprising a water-soluble vinorelbine salt and at least one diluent and one lubricant, characterized in that it appears in a solid form intended for oral administration. The water soluble vinorelbine salt is advantageously vinorelbine ditartrate. The pharmaceutical composition advantageously appears as a gelatin capsule or tablet.